Table 3

Summary of key results

Previous knowledge in the field
 • Empagliflozin and canagliflozin reduce risk of MACE, but whether this is a class effect remains to be established.
 • The CVOTs for empagliflozin, canagliflozin, and dapagliflozin enrolled populations with different cardiovascular risks; whether patients without existing CVD will receive cardiovascular benefit from SGLT2i remains unclear.
 • SGLT2i are known to improve eGFR and albuminuria, but differences in end point definition make between-trial and between-drug comparisons difficult.
New insights from this study
 • This study examined users of three different SGLT2i within the same rigorously collected global clinical trial with adjudicated MACE and ACM, providing new support for a class effect.
 • Although event numbers were low, this analysis suggests that SGLT2i may also reduce cardiovascular risk in subjects without diagnosed CVD.
 • SGLT2i as a class, including dapagliflozin, have a positive effect on eGFR slope in a population with preserved eGFR and predominantly normoalbuminuria at baseline.